7 Things Vertex Pharmaceuticals' CEO Just Said That Will Probably Make You Want to Buy the Stock [The Motley Fool]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: The Motley Fool
The only "problem" mentioned by Vertex CEO Jeff Leiden? It's accumulating cash rapidly. Vertex Pharmaceuticals ( NASDAQ:VRTX ) achieved something in 2017 that few stocks did: It more than doubled. At the beginning of this year, I picked Vertex as one of the top big biotech stocks to buy . That pick has looked good so far. Vertex is off to a great start in 2018, with a year-to-date gain of more than 15%. But is it too late to buy this hot biotech stock now? I don't think so, especially after listening to Jeff Leiden, Vertex's CEO, speak on Wednesday at the Cowen healthcare conference. Here are seven things Leiden said that just might make you want to buy the stock. Image source: Getty Images. 1. Completing the journey in cystic fibrosis is only a matter of execution Vertex enjoys a monopoly in the cystic fibrosis (CF) market with three drugs -- Kalydeco, Orkambi, and recently approved Symdeko. The company's goal over the next couple of years or so is to prov
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Vertex (VRTX), TreeFrog Sign Deal for Diabetes Cell Therapies [Yahoo! Finance]Yahoo! Finance
- Vertex in-licenses cell therapy technology for diabetes candidates [Seeking Alpha]Seeking Alpha
- Global Vaccine Contract Manufacturing Market Trends Analysis Report 2024-2030: Capacity Expansion by Contract Manufacturers, & Vaccination Innovation and Robust Vaccine Pipeline Bolsters Growth [Yahoo! Finance]Yahoo! Finance
- Arcturus Therapeutics' ARCT-032: Might Be The Next Breakthrough In Cystic Fibrosis [Seeking Alpha]Seeking Alpha
- U.S. Gene Therapy Market Size, Share & Trends Analysis Report 2024-2030: Robust Pipeline and Growing Prevalence of Target Diseases Fueling Growth and Developments [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/17/24 - Form 4
- 4/16/24 - Form PX14A6G
- 4/11/24 - Form SC
- VRTX's page on the SEC website